Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) Shares Outstanding (Diluted Average) (2021 - 2025)

Cue Biopharma's Shares Outstanding (Diluted Average) history spans 5 years, with the latest figure at $100.9 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Diluted Average) rose 96.9% year-over-year to $100.9 million; the TTM value through Sep 2025 reached $100.9 million, up 96.9%, while the annual FY2024 figure was $56.3 million, 23.11% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q3 2025 was $100.9 million at Cue Biopharma, up from $95.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $100.9 million in Q3 2025 and bottomed at $31.3 million in Q4 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $45.8 million (2023), against an average of $50.5 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) increased 10.08% in 2022 before it skyrocketed 96.9% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $31.3 million in 2021, then grew by 13.95% to $35.6 million in 2022, then grew by 28.35% to $45.8 million in 2023, then grew by 23.11% to $56.3 million in 2024, then skyrocketed by 79.07% to $100.9 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Shares Outstanding (Diluted Average) are $100.9 million (Q3 2025), $95.5 million (Q2 2025), and $74.3 million (Q1 2025).